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Abstract About 20 years ago an American study suggested
that daily subcutaneous injections of a metabolically inactive
insulin analogue with a single amino acid substitution
(aspartic acid instead of phenylalanine) at position 25 of the
B chain was as effective as intact insulin in preventing auto-
immune diabetes in NOD mice. In this issue of Diabetologia
Grönholm et al (DOI: 10.1007/s00125-017-4276-5) report
that parenteral administration of the same insulin analogue
has no preventive effect whatsoever on the development of
diabetes in NODmice; in fact, high doses of the metabolically
inactive insulin accelerated disease development. The authors
were also unable to show any tolerogenic effect of an insulin
peptide mimetope given via a subcutaneous osmotic pump.
These data do not support the use of metabolically inactive
insulin for the prevention of autoimmune diabetes and
question whether insulin alone, intact or inactivated has any
role in preventing progression to symptomatic diabetes.
Future and ongoing intervention trials in humans with
preclinical type 1 diabetes should indicate whether the
administration of oral insulin has any protective, neutral or
even predisposing effects on the development of
symptomatic diabetes.






MII Metabolically inactive insulin analogue
PD-L1 Programmed death-ligand 1
Introduction
Insulin has been perceived as the primary autoantigen in au-
toimmune diabetes both in humans [1] and in NOD mice [2].
Consequently insulin has been used widely in studies apply-
ing antigen-specific therapy for the prevention of type 1 dia-
betes. Earlier studies have shown that oral, nasal and subcu-
taneous administration of insulin to prediabetic NOD mice
protects to a variable degree against progression to clinical
disease [3]. However, studies in humans have, so far, been
unable to show any protective effect of insulin against the
development of type 1 diabetes even when using different
routes of administration. The only exception is the post hoc
subgroup analysis in the oral arm of the Diabetes Prevention
Trial (DPT-1) that showed a delayed progression to clinical
disease among the participants with high insulin autoantibody
(IAA) titres [4]. The contrast between NODmice and humans
in the success of preventive interventions implies that there are
fundamental differences in the disease process leading to au-
toimmune diabetes in mice and type 1 diabetes in humans [5].
Recent studies have suggested that type 1 diabetes is a
heterogeneous disease in terms of which autoantibody appears
first [6, 7]. IAAs are the first autoantibodies in more than half
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of prospectively observed children with HLA-conferred dis-
ease susceptibility, turning subsequently positive for multiple
(more than two) autoantibodies, while close to 40% present
with GAD antibodies as their first autoantibodies. Islet antigen
2 and zinc transporter 8 antibodies are rarely the first autoan-
tibody reactivity to emerge. The observed heterogeneity raises
the issue of whether there are different primary autoantigens in
humans and whether the autoantibodies emerging first are
markers of such a difference. If so, that difference should be
taken into account when planning antigen-specific immuno-
therapy in preclinical type 1 diabetes. In autoimmune diabetes
in NOD mice the role of insulin as the primary autoantigen
appears to be more robust, although other autoantigens, such
as islet-specific glucose-6-phosphatase catalytic subunit-
related protein (IGRP), have been identified [8].
Metabolically inactive insulin in prevention
of autoimmune diabetes
In 1995, Muir et al reported that immunisation with insulin or
the metabolically inactive B chain in prediabetic NOD mice
converts a destructive insulitis into a protective one by
inhibiting the expression of Ifng mRNA (encoding IFNγ) in
the insulitis lesions [9]. Two years later Karounos et al ob-
served that daily s.c. injections of a metabolically inactive
insulin analogue (MII) with a single amino acid substitution
(aspartic acid instead of phenylalanine) at position 25 of the B
chain was as effective as intact insulin in preventing autoim-
mune diabetes in NOD mice [10]. The protective effect was
seen in young adult mice even when the treatment was started
after the appearance of extensive lymphocyte infiltration into
the pancreatic islets. These observations indicated that the
protective therapy did not require a hypoglycaemic response
or binding to the insulin receptor to be effective.
Grönholm and collaborators used a similar MII in their
study published in this issue of Diabetologia [11]. They treat-
ed non-diabetic 8-week-old female NOD mice with s.c. MII
injections at constant doses of 2 μg, 20 μg or 200 μg twice
weekly for 5 weeks. In addition one group of mice was treated
with a ramp up dose from 2 μg to 200 μg over the 5 week
period. The authors did not observe any delay or protection
from autoimmune diabetes but, in contrast, the higher doses of
20 μg or 200 μg accelerated disease development. Since
Karounos et al had given the MII daily, 5 μg was adminis-
tered daily to a group of sevenmice in the current study, but no
preventive effect could be seen. The authors also tested wheth-
er any protective effect could be induced by administering the
insulin peptide mimetope 3, which has previously been shown
to prevent autoimmune diabetes [12]. No tolerogenic induc-
tion could be observed, however.
The authors set out to assess whether high i.v. doses
of MII could induce tolerance. For this purpose 7-
week-old NOD mice were injected intravenously with
400 μg MII or PBS twice weekly. Diabetes appeared slightly
earlier in thosemice treated with theMII. In one group of mice
CD8+ T cells were stained with tetramers for insulin and
IGRP at 16 weeks at age. No differences were observed be-
tween theMII-treated mice and the control mice in the number
of tetramer-reactive CD8+ cells in the pancreas, pancreatic
draining lymph nodes or the spleen. In addition the authors
tested the impact of different dosing schemes for the i.v. in-
jections (twice a day or every other day) but no protective
effects could be observed. The i.v. treatment at high doses
resulted in an increased number of insulin-reactive CD4+ T
cells in the peripheral lymphoid tissue. Further, the authors
analysed the outcome of i.v. administration of MII in 7-
week-old NOD mice treated with parenteral anti-
programmed death-ligand 1 (PD-L1) to investigate whether
MII is capable of preventing anti-PD-L1-induced diabetes in
NOD mice given that anti-PD-L1 can accelerate the develop-
ment of autoimmune diabetes [13]. The combination of anti-
PD-L1 and MII turned out to accelerate the progression of
autoimmune diabetes.
Strengths and limitations of the current study
The study by Grönholm et al was well planned and the
methods applied were appropriate. Different doses of MII as
well as different administration routes were assessed. As the
authors had access to mice colonies at three sites, some tests
were carried out in two different NOD colonies, with identical
outcomes. The authors also provided data on the statistical
power of their study.
A major limitation of the study is the limited immune-
phenotyping data available. FACS and functional analyses
of regulatory T cells and effector T cell subsets could provide
important information on treatment mechanisms. Initiation of
therapy at an earlier age should be assessed, since the timing
of therapy might change the outcome.
Why do the outcomes of the current study differ
from previous studies?
The current study showed that parenteral administration of
MII was unable to induce in vivo tolerance and to protect
against progression to autoimmune diabetes in NOD mice.
In fact, high doses of MII accelerated disease progression.
These observations are in contrast with previous studies
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reporting that daily parenteral administration of intact insulin
or an MII prevents insulitis and diabetes in NOD mice.
There are some differences between the current study,
with a negative outcome of MII treatment, and the study
by Karounos et al [10], which reported a protective effect
of MII. The amino acid in position B30 (alanine) was
removed from the analogue used in the current study but
was present in the analogue tested by Karounos et al. This
amino acid has been observed to eliminate the induction
of oral tolerance in NOD mice [14]. Therefore, one would
expect that its removal would strengthen rather than re-
duce the preventive effect of the analogue. There was also
a difference in the diluents used between the two studies.
Karounos and collaborators used m-cresol, phenol, glyc-
erine and sodium phosphate diluted in water, while
Grönholm et al used PBS. One cannot exclude the pos-
sibility that the diluent might affect the therapeutic effica-
cy of the analogue, although it seems unlikely. The cur-
rent study used a dosing scheme with injections twice
weekly, whereas the earlier study administered MII daily.
However, Grönholm et al also measured the effect of
daily MII administration without any change in the nega-
tive outcome. Therefore, there is no definitive explanation
for the contrasting outcomes of the two studies.
Conclusions
The study by Grönholm and collaborators indicates that
parenteral administration of an MII does not provide any
protective effect in terms of progression to autoimmune
diabetes in NOD mice. Previous studies have indicated
that repeated doses of insulin administered by oral, nasal
or parenteral routes can prevent diabetes in NOD mice.
The current study does not contradict those observations,
but the outcome is in contrast with the results of previous
studies testing the preventive effect of MIIs or the insulin
B chain, which also lacks hormonal effects. The reasons
underlying the conflicting results remain open for the time
being.
Thus far, the translation of the protective effects of
insulin in NOD mice to humans with type 1 diabetes
has not come to light. This reflects the fact that the pre-
vention of type 1 diabetes is definitely more challenging
than the prevention of autoimmune diabetes in NOD
mice. The next piece of the jigsaw regarding the effect
of oral administration of insulin to autoantibody-positive
relatives of individuals with type 1 diabetes will be un-
covered when the results of the oral insulin trial within
TrialNet (ClinicalTrials.gov NCT00419562) become
available.
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